Résumé
This study was to investigate the anti-obesity effects of diglyceride (DG)-conjugated linoleic acid (CLA) containing 22% CLA as fatty acids in C57BL/6J ob/ob male mice. There were four experimental groups including vehicle control, DG, CLA, and DG-CLA. The test solutions of 750 mg/kg dose were orally administered to the mice everyday for 5 weeks. CLA treatments significantly decreased mean body weight in the obese mice throughout the experimental period compared to the control (p < 0.01). All test solutions significantly decreased the levels of triglyceride, glucose and free fatty acids in the serum compared with control (p < 0.05). The levels of total cholesterol were also significantly reduced in DG and DG-CLA groups compared with the control group (p < 0.05). CLA significantly decreased weights of renal and epididymal fats compared with the control (p < 0.05). DG and DG-CLA also significantly decreased the epididymal fat weights compared with the control (p < 0.05). A remarkable decrease in the number of lipid droplets and fat globules was observed in the livers of mice treated with DG, CLA, and DG-CLA compared to control. Treatments of DG and CLA actually increased the expression of peroxisome proliferator-activated receptor gamma. These results suggest that DG-CLA containing 22% CLA have a respectable anti-obesity effect by controlling serum lipids and fat metabolism.
Sujets)
Animaux , Mâle , Souris , Tissu adipeux/effets des médicaments et des substances chimiques , Agents antiobésité/pharmacologie , Analyse chimique du sang , Poids/effets des médicaments et des substances chimiques , Diglycéride/pharmacologie , Modèles animaux de maladie humaine , Consommation alimentaire/effets des médicaments et des substances chimiques , Régulation de l'expression des gènes/effets des médicaments et des substances chimiques , Acides linoléiques conjugués/pharmacologie , Lipides/sang , Foie/effets des médicaments et des substances chimiques , Souris de lignée C57BL , Souris obèse , Obésité/métabolisme , Récepteur PPAR gamma/métabolisme , Facteurs tempsRésumé
No abstract available.